文献速递白血病

NF1突变在成人急性髓系白血病中反复出现并导致不良结局

NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome.
PubMed 文献 · Leukemia · 2018-06-05

对1021例成人初发急性髓系白血病(AML)患者进行81个基因的靶向突变检测,发现52例(5.1%)存在NF1基因反复突变,包括36例(5.2%)年轻患者和16例(4.8%)老年患者。NF1突变患者更多属于欧洲白血病网(ELN)不良风险类别;在年龄<60岁患者中,NF1 Thr676突变与较低完全缓解(CR)率和较短总生存(OS)相关(CR P=0.04;OS P=0.01),在ELN不良风险类别患者中任何NF1突变亦与较低CR率和较短OS相关(CR P=0.05;OS P<0.001);年龄≥60岁NF1突变患者CR率也低于NF1野生型患者(P=0.001)。

要点

  • 1021例成人初发AML中52例(5.1%)存在NF1突变,包括36例(5.2%)年轻和16例(4.8%)老年患者。
  • NF1突变患者更多属于ELN不良风险类别,Thr676热点占NF1突变患者的27%。
  • 年龄<60岁患者中NF1 Thr676突变与较低CR率(P=0.04)和较短OS(P=0.01)相关。

核心结论

  • 本研究发现NF1突变在成人AML中反复出现,并提示在接受标准化疗的患者中具有不良预后影响。

研究设计与样本

  • 对1021例成人初发急性髓系白血病(AML)患者进行81个基因的靶向突变检测。

主要发现

  • 52例(5.1%)患者存在NF1反复突变,包括36例(5.2%)年轻患者和16例(4.8%)老年患者。
  • NF1突变遍布整个基因,包括错义、移码和无义突变;氨基酸苏氨酸676(Thr676)热点见于27%的NF1突变AML患者。
  • NF1突变患者更多属于欧洲白血病网(ELN)不良风险类别。
  • 年龄<60岁患者中,NF1 Thr676突变与较低完全缓解(CR)率(P=0.04)和较短总生存(OS;P=0.01)相关;在ELN不良风险类别患者中,任何NF1突变与较低CR率(P=0.05)和较短OS(P<0.001)相关。
  • 年龄≥60岁NF1突变患者CR率低于NF1野生型患者(P=0.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeted mutation assessment of 81 genes in 1021 adults with de novo acute myeloid leukemia (AML) identified recurrent mutations in the neurofibromin 1 (NF1) gene in 52 (5.1%) patients, including 36 (5.2%) younger and 16 (4.8%) older patients, which suggests NF1 belongs to the 20 most frequently mutated genes in adult AML. NF1 mutations were found throughout the gene, and comprised missense, frameshift, and nonsense mutations. One mutation hotspot, at amino acid threonine 676 (Thr676), was found in 27% of AML patients with NF1 mutations. NF1-mutated patients belonged more often to the adverse European LeukemiaNet (ELN) risk category than NF1 wild-type patients. Among patients aged <60 years, the presence of NF1 Thr676 mutations was associated with lower complete remission (CR) rates (P = 0.04) and shorter overall survival (OS; P = 0.01), as was the presence of any NF1 mutation in patients in the adverse ELN risk category (CR, P = 0.05; OS, P < 0.001). CR rates were also lower in NF1-mutated patients aged ≥60 years compared with NF1 wild-type patients (P = 0.001). In summary, our findings provide novel insights into the frequency of NF1 mutations in AML, and are suggestive of an adverse prognostic impact in patients treated with standard chemotherapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Eisfeld AK, Kohlschmidt J, Mrózek K, et al. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018. PMID: 29872168. doi:10.1038/s41375-018-0147-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。